SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
Titel:
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
Auteur:
Hoffmann, Markus Hofmann-Winkler, Heike Krüger, Nadine Kempf, Amy Nehlmeier, Inga Graichen, Luise Arora, Prerna Sidarovich, Anzhalika Moldenhauer, Anna-Sophie Winkler, Martin S. Schulz, Sebastian Jäck, Hans-Martin Stankov, Metodi V. Behrens, Georg M.N. Pöhlmann, Stefan